Sotera Health (NASDAQ:SHC) Updates FY24 Earnings Guidance

by · The Cerbat Gem

Sotera Health (NASDAQ:SHC – Get Free Report) updated its FY24 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $0.67-0.75 for the period, compared to the consensus estimate of $0.72. The company issued revenue guidance of $1.09-1.11 billion, compared to the consensus revenue estimate of $1.11 billion. Sotera Health also updated its FY 2024 guidance to 0.670-0.750 EPS.

Wall Street Analyst Weigh In

Several brokerages recently commented on SHC. Royal Bank of Canada reissued an “outperform” rating and set a $17.00 price target on shares of Sotera Health in a research report on Tuesday, August 6th. Citigroup lifted their price objective on shares of Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Barclays raised their target price on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, August 6th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Get Our Latest Report on SHC

Sotera Health Price Performance

Shares of SHC stock traded up $0.47 on Wednesday, reaching $15.89. The company’s stock had a trading volume of 929,339 shares, compared to its average volume of 1,304,662. The company has a market capitalization of $4.50 billion, a price-to-earnings ratio of 112.93 and a beta of 2.08. The stock’s fifty day simple moving average is $15.94 and its 200-day simple moving average is $13.67. The company has a current ratio of 2.93, a quick ratio of 2.59 and a debt-to-equity ratio of 5.46. Sotera Health has a 1 year low of $10.71 and a 1 year high of $17.44.

Sotera Health (NASDAQ:SHC – Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). Sotera Health had a return on equity of 47.26% and a net margin of 3.65%. The company had revenue of $285.47 million during the quarter, compared to the consensus estimate of $278.64 million. During the same period in the previous year, the firm posted $0.18 earnings per share. The company’s revenue was up 8.5% on a year-over-year basis. Analysts forecast that Sotera Health will post 0.64 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $15.03, for a total transaction of $150,300,000.00. Following the transaction, the director now owns 49,215,301 shares in the company, valued at approximately $739,705,974.03. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 55.12% of the stock is currently owned by insiders.

About Sotera Health

(Get Free Report)

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.

See Also